News & Updates

Erlotinib + BSC fares better than BSC alone for gall bladder cancer

03 Aug 2022 by

The addition of erlotinib to best supportive care (BSC) provided better survival benefit than BSC only in individuals with unresectable/metastatic gall bladder cancer (GBC) with poor performance status (PS), according to a phase II/III open-label study.

Erlotinib + BSC fares better than BSC alone for gall bladder cancer

03 Aug 2022

Healthy living key to reducing lethal prostate cancer risk

02 Aug 2022 by

Adhering to a healthy lifestyle may be a means to counteract the genetic risk of lethal prostate cancer, a study finds.

Healthy living key to reducing lethal prostate cancer risk

02 Aug 2022

Online intervention shows promise in psych support for partners of cancer patients

31 Jul 2022

PartnerCARE, an online intervention designed to address mental health needs of caregiving partners of cancer patients, appears to be feasible and acceptable, a recent study has found. PartnerCARE also appears to be effective, inducing substantial improvements in psychological distress and anxiety.

Online intervention shows promise in psych support for partners of cancer patients

31 Jul 2022

Many cancer patients cannot cope with depressive symptoms

31 Jul 2022

A large proportion of cancer patients suffering from depressive symptoms cannot seem to effectively manage this burden on their own, particularly those who tend to avoid dealing with their own problems, reports a recent analysis.

Many cancer patients cannot cope with depressive symptoms

31 Jul 2022

Original New Drug Application Approvals by US FDA (16 - 31 July 2022)

31 Jul 2022

New drug applications approved by US FDA as of 16 - 31 July 2022 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (16 - 31 July 2022)

31 Jul 2022

Is pre-emptive pharmacogenetic testing in CRC patients viable within a community oncology clinic?

30 Jul 2022

A recent study has shown that it is possible to implement pre-emptive pharmacogenetic testing into a community-based oncology clinic with results interpretation available for colorectal cancer patients before their scheduled initiation of chemotherapy.

Is pre-emptive pharmacogenetic testing in CRC patients viable within a community oncology clinic?

30 Jul 2022

Pembro + chemo prolongs OS in TNBC patients with high PD-L1 expression

30 Jul 2022 by

Adding pembrolizumab to chemotherapy in the first-line setting significantly prolongs overall survival (OS) in patients with triple-negative breast cancer (TNBC) whose tumours expressed programmed death-ligand 1 (PD-L1) with a CPS* of ≥10, compared with chemotherapy alone, according to the KEYNOTE-355** trial.

Pembro + chemo prolongs OS in TNBC patients with high PD-L1 expression

30 Jul 2022

Polypharmacy, steep out-of-pocket costs hound cancer patients at end of life

29 Jul 2022

Polypharmacy frequently occurs in most patients with advanced cancer at end of life, reports a recent study. However, most medications used are usually for supportive care.

Polypharmacy, steep out-of-pocket costs hound cancer patients at end of life

29 Jul 2022

Mold infections after haematopoietic stem cell transplant higher than expected

28 Jul 2022

The incidence of proven or probable invasive mold infection in a real-life cohort of allogeneic haematopoietic stem cell transplantation recipients is higher than that seen in previous literature, according to a recent study.

Mold infections after haematopoietic stem cell transplant higher than expected

28 Jul 2022

Gut microbiota altered in prostate cancer

27 Jul 2022 by

Men with prostate cancer have altered gut microbiota composition, according to a study presented at the recent Annual Congress of the European Association of Urology (EAU 2022). This association may partly explain the documented links between lifestyle or geographic location and prostate cancer.

Gut microbiota altered in prostate cancer

27 Jul 2022

News & Updates

Filter by Specialty:

Specialty:

Erlotinib + BSC fares better than BSC alone for gall bladder cancer

Erlotinib + BSC fares better than BSC alone for gall bladder cancer

Healthy living key to reducing lethal prostate cancer risk

Healthy living key to reducing lethal prostate cancer risk

Online intervention shows promise in psych support for partners of cancer patients

Online intervention shows promise in psych support for partners of cancer patients

Many cancer patients cannot cope with depressive symptoms

Many cancer patients cannot cope with depressive symptoms

Original New Drug Application Approvals by US FDA (16 - 31 July 2022)

Original New Drug Application Approvals by US FDA (16 - 31 July 2022)

Is pre-emptive pharmacogenetic testing in CRC patients viable within a community oncology clinic?

Is pre-emptive pharmacogenetic testing in CRC patients viable within a community oncology clinic?

Pembro + chemo prolongs OS in TNBC patients with high PD-L1 expression

Pembro + chemo prolongs OS in TNBC patients with high PD-L1 expression

Polypharmacy, steep out-of-pocket costs hound cancer patients at end of life

Polypharmacy, steep out-of-pocket costs hound cancer patients at end of life

Mold infections after haematopoietic stem cell transplant higher than expected

Mold infections after haematopoietic stem cell transplant higher than expected

Gut microbiota altered in prostate cancer

Gut microbiota altered in prostate cancer